Lamotrigine and its applications in the treatment of epilepsy and other neurological and psychiatric disorders

References

• Hauser WA, Annegers JF, Kurland LT. Prevalence of epilepsy in Rochester, Minnesota: 1940–1980. Epilepsia32(4), 429–445 (1991).
   PubMed Web of Science ®Google Scholar
• Begley CE, Annegers JF, Lairson DR, Reynolds TF, Hauser WA. Cost of epilepsy in the United States: a model based on incidence and prognosis. Epilepsia35(6), 1230–1243 (1994).
   PubMed Web of Science ®Google Scholar
• Kotsopoulos IA, van Merode T, Kessels FG, de Krom MC, Knottnerus JA. Systematic review and meta-analysis of incidence studies of epilepsy and unprovoked seizures. Epilepsia43(11), 1402–1409 (2002).
   PubMed Web of Science ®Google Scholar
• Kwan P, Brodie MJ. Early identification of refractory epilepsy. N. Engl. J. Med.342(5), 314–319 (2000).
   PubMed Web of Science ®Google Scholar
• Regesta G, Tanganelli P. Clinical aspects and biological bases of drug-resistant epilepsies. Epilepsy Res.34(2–3), 109–122 (1999).
   PubMed Web of Science ®Google Scholar
• Bowden CL, Calabrese JR, Sachs G et al. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder. Arch. Gen. Psychiatry60(4), 392–400 (2003).
   PubMed Web of Science ®Google Scholar
• Cusin C, Serretti A, Lattuada E, Mandelli L, Smeraldi E. Impact of clinical variables on illness time course in mood disorders. Psychiatry Res.97(2–3), 217–227 (2000).
   PubMedGoogle Scholar
• Hommes OR, Obbens EA. The epileptogenic action of Na-folate in the rat. J. Neurol. Sci.16(3), 271–281 (1972).
   PubMedGoogle Scholar
• Choi H, Morrell MJ. Review of lamotrigine and its clinical applications in epilepsy. Expert Opin. Pharmacother.4(2), 243–251 (2003).
   PubMed Web of Science ®Google Scholar
• Lamictal® package insert. Glaxo Smith Kline, NC, USA.
   Google Scholar
• Gilliam F, Vazquez B, Sackellares JC et al. An active-control trial of lamotrigine monotherapy for partial seizures. Neurology51(4), 1018–1025 (1998).
   PubMed Web of Science ®Google Scholar
• Posner EB, Mohamed K, Marson AG. Ethosuximide, sodium valproate or lamotrigine for absence seizures in children and adolescents. Cochrane Database Syst. Rev. (4), CD003032 (2005).
   Google Scholar
• Mikati MA, Holmes GL. Lamotrigine in absence and primary generalized epilepsies. J. Child Neurol.12(Suppl. 1), S29–S37 (1997).
   PubMed Web of Science ®Google Scholar
• Frank LM, Enlow T, Holmes GL et al. Lamictal (lamotrigine) monotherapy for typical absence seizures in children. Epilepsia40(7), 973–979 (1999).
   PubMed Web of Science ®Google Scholar
• Coppola G, Auricchio G, Federico R, Carotenuto M, Pascotto A. Lamotrigine versus valproic acid as first-line monotherapy in newly diagnosed typical absence seizures: an open-label, randomized, parallel-group study. Epilepsia45(9), 1049–1053 (2004).
   PubMedGoogle Scholar
• Moshe SL. Mechanisms of action of anticonvulsant agents. Neurology55(5 Suppl. 1), S32–S40; discussion S54–S38 (2000).
   Google Scholar
• Castel-Branco MM, Falcao AC, Figueiredo IV, Caramona MM. Lamotrigine pharmacokinetic/pharmacodynamic modelling in rats. Fundam. Clin. Pharmacol.19(6), 669–675 (2005).
   PubMed Web of Science ®Google Scholar
• Waldmeier PC, Baumann PA, Wicki P, Feldtrauer JJ, Stierlin C, Schmutz M. Similar potency of carbamazepine, oxcarbazepine, and lamotrigine in inhibiting the release of glutamate and other neurotransmitters. Neurology45(10), 1907–1913 (1995).
   PubMed Web of Science ®Google Scholar
• Stefani A, Spadoni F, Siniscalchi A, Bernardi G. Lamotrigine inhibits Ca2+ currents in cortical neurons: functional implications. Eur. J. Pharmacol.307(1), 113–116 (1996).
   PubMed Web of Science ®Google Scholar
• Wang SJ, Huang CC, Hsu KS, Tsai JJ, Gean PW. Inhibition of N-type calcium currents by lamotrigine in rat amygdalar neurones. Neuroreport7(18), 3037–3040 (1996).
   PubMed Web of Science ®Google Scholar
• Wang SJ, Sihra TS, Gean PW. Lamotrigine inhibition of glutamate release from isolated cerebrocortical nerve terminals (synaptosomes) by suppression of voltage-activated calcium channel activity. Neuroreport12(10), 2255–2258 (2001).
   PubMed Web of Science ®Google Scholar
• Hainsworth AH, McNaughton NC, Pereverzev A, Schneider T, Randall AD. Actions of sipatrigine, 202W92 and lamotrigine on R-type and T-type Ca2+ channel currents. Eur. J. Pharmacol.467(1–3), 77–80 (2003).
   PubMed Web of Science ®Google Scholar
• Pisani A, Bonsi P, Martella G et al. Intracellular calcium increase in epileptiform activity: modulation by levetiracetam and lamotrigine. Epilepsia45(7), 719–728 (2004).
   PubMed Web of Science ®Google Scholar
• Zona C, Tancredi V, Longone P et al. Neocortical potassium currents are enhanced by the antiepileptic drug lamotrigine. Epilepsia43(7), 685–690 (2002).
   PubMed Web of Science ®Google Scholar
• Shiah IS, Yatham LN, Gau YC, Baker GB. Effect of lamotrigine on plasma gamma-aminobutyric acid (GABA) levels in healthy humans. Prog. Neuropsychopharmacol. Biol. Psychiatry27(3), 419–423 (2003).
   PubMedGoogle Scholar
• Cohen AF, Land GS, Breimer DD, Yuen WC, Winton C, Peck AW. Lamotrigine, a new anticonvulsant: pharmacokinetics in normal humans. Clin. Pharmacol. Ther.42(5), 535–541 (1987).
   PubMed Web of Science ®Google Scholar
• Peck AW. Clinical pharmacology of lamotrigine. Epilepsia32(Suppl. 2), S9–S12 (1991).
   PubMedGoogle Scholar
• Ramsay RE, Pellock JM, Garnett WR et al. Pharmacokinetics and safety of lamotrigine (Lamictal) in patients with epilepsy. Epilepsy Res.10(2–3), 191–200 (1991).
   PubMed Web of Science ®Google Scholar
• Hirsch LJ, Weintraub D, Du Y et al. Correlating lamotrigine serum concentrations with tolerability in patients with epilepsy. Neurology63(6), 1022–1026 (2004).
   PubMed Web of Science ®Google Scholar
• Bialer M. The pharmacokinetics and interactions of new antiepileptic drugs: an overview. Ther. Drug Monit.27(6), 722–726 (2005).
   PubMed Web of Science ®Google Scholar
• Yuen AW, Peck AW. Lamotrigine pharmacokinetics: oral and intravenous infusion in man. Br. J. Clin. Pharmacol.26, 242 (1988).
   Web of Science ®Google Scholar
• Richens A. Pharmacokinetics of lamotrigine. In: Clinical Update on Lamotrigine: A Novel Antiepileptic Agent. Richens A (Ed.). Wells Medical Limited, Kent, UK, 21–27 (1992).
   Google Scholar
• Yuen AW, Land G, Weatherley BC, Peck AW. Sodium valproate acutely inhibits lamotrigine metabolism. Br. J. Clin. Pharmacol.33(5), 511–513 (1992).
   PubMed Web of Science ®Google Scholar
• Weintraub D, Buchsbaum R, Resor SR Jr, Hirsch LJ. Effect of antiepileptic drug comedication on lamotrigine clearance. Arch Neurol.62(9), 1432–1436 (2005).
   PubMed Web of Science ®Google Scholar
• Holdish T, Whiteman P, Orme M. Effect of lamotrgine on the pharmacology of the combined oral contraceptive pill. Epilepsia32(Suppl. 5), 173 (1991).
   Google Scholar
• Sabers A, Ohman I, Christensen J, Tomson T. Oral contraceptives reduce lamotrigine plasma levels. Neurology61(4), 570–571 (2003).
   PubMed Web of Science ®Google Scholar
• Sabers A, Buchholt JM, Uldall P, Hansen EL. Lamotrigine plasma levels reduced by oral contraceptives. Epilepsy Res.47(1–2), 151–154 (2001).
   PubMed Web of Science ®Google Scholar
• Reimers A, Helde G, Brodtkorb E. Ethinyl estradiol, not progestogens, reduces lamotrigine serum concentrations. Epilepsia46(9), 1414–1417 (2005).
   PubMed Web of Science ®Google Scholar
• Wootton R, Soul-Lawton J, Rolan PE, Sheung CT, Cooper JD, Posner J. Comparison of the pharmacokinetics of lamotrigine in patients with chronic renal failure and healthy volunteers. Br. J. Clin. Pharmacol.43(1), 23–27 (1997).
   PubMed Web of Science ®Google Scholar
• Fillastre JP, Taburet AM, Fialaire A, Etienne I, Bidault R, Singlas E. Pharmacokinetics of lamotrigine in patients with renal impairment: influence of haemodialysis. Drugs Exp. Clin. Res.19(1), 25–32 (1993).
   PubMedGoogle Scholar
• Kroemer HK, Klotz U. Glucuronidation of drugs. A re-evaluation of the pharmacological significance of the conjugates and modulating factors. Clin. Pharmacokinet.23(4), 292–310 (1992).
   PubMed Web of Science ®Google Scholar
• Posner J, Cohen AF, Land G, Winton C, Peck AW. The pharmacokinetics of lamotrigine (BW430C) in healthy subjects with unconjugated hyperbilirubinaemia (Gilbert’s syndrome). Br. J. Clin. Pharmacol.28(1), 117–120 (1989).
   PubMed Web of Science ®Google Scholar
• Marcellin P, de Bony F, Garret C et al. Influence of cirrhosis on lamotrigine pharmacokinetics. Br. J. Clin. Pharmacol.51(5), 410–414 (2001).
   PubMed Web of Science ®Google Scholar
• Chan V, Morris RG, Ilett KF, Tett SE. Population pharmacokinetics of lamotrigine. Ther. Drug Monit.23(6), 630–635 (2001).
   PubMed Web of Science ®Google Scholar
• Hussein Z, Posner J. Population pharmacokinetics of lamotrigine monotherapy in patients with epilepsy: retrospective analysis of routine monitoring data. Br. J. Clin. Pharmacol.43(5), 457–465 (1997).
   PubMed Web of Science ®Google Scholar
• Posner J, Holdrich T, Crome P. Comparison of lamotrigine pharmacokinetics in young and elderly healthy volunteers. J. Pharm. Med.1, 121–128 (1991).
   Google Scholar
• Hirsch LJ, Weintraub D, Spencer HT et al. Lamotrigine tolerability and serum blood levels: comparison of 686 levels in 121 older adults to 920 levels in 214 younger adults. Presented at: International Geriatric Epilepsy Symposium. Miami, FL, USA (2003).
   Google Scholar
• Ohman I, Vitols S, Tomson T. Lamotrigine in pregnancy: pharmacokinetics during delivery, in the neonate, and during lactation. Epilepsia41(6), 709–713 (2000).
   PubMed Web of Science ®Google Scholar
• Mikati MA, Fayad M, Koleilat M et al. Efficacy, tolerability, and kinetics of lamotrigine in infants. J. Pediatr.141(1), 31–35 (2002).
   PubMedGoogle Scholar
• Bartoli A, Guerrini R, Belmonte A, Alessandri MG, Gatti G, Perucca E. The influence of dosage, age, and comedication on steady state plasma lamotrigine concentrations in epileptic children: a prospective study with preliminary assessment of correlations with clinical response. Ther. Drug Monit.19(3), 252–260 (1997).
   PubMed Web of Science ®Google Scholar
• Chen C, Casale EJ, Duncan B, Culverhouse EH, Gilman J. Pharmacokinetics of lamotrigine in children in the absence of other antiepileptic drugs. Pharmacotherapy19(4), 437–441 (1999).
   PubMed Web of Science ®Google Scholar
• Pack AM. Therapy insight: clinical management of pregnant women with epilepsy. Nat. Clin. Pract.Neurol.2(4), 190–200 (2006).
   PubMedGoogle Scholar
• Stables JP, Bialer M, Johannessen SI et al. Progress report on new antiepileptic drugs. A summary of the Second Eilat Conference. Epilepsy Res.22(3), 235–246 (1995).
   PubMedGoogle Scholar
• Candito M, Gueant JL, Naimi M, Bongain A, Van Obberghen E. Antiepileptic drugs: a case report in a pregnancy with a neural tube defect. Pediatr. Neurol.34(4), 323–324 (2006).
   PubMed Web of Science ®Google Scholar
• Cunnington M, Tennis P. Lamotrigine and the risk of malformations in pregnancy. Neurology64(6), 955–960 (2005).
   PubMed Web of Science ®Google Scholar
• Vajda F, Lander C, O’Brien T et al. Australian pregnancy registry of women taking antiepileptic drugs. Epilepsia45(11), 1466 (2004).
   PubMed Web of Science ®Google Scholar
• Morrow J, Russell A, Guthrie E et al. Malformation risks of antiepileptic drugs in pregnancy: a prospective study from the UK Epilepsy and Pregnancy Register. J. Neurol. Neurosurg. Psychiatry77(2), 193–198 (2006).
   PubMed Web of Science ®Google Scholar
• Holmes LB, Wyszynski DF, Baldwin EJ, Habecker E, Glassman LH, Smith CR. Increased risk for non-syndromic cleft palate among infants exposed to lamotrigine during pregnancy. Birth Defects Res. Part A Clin. Mol. Teratol.76(5), 318 (2006).
   Google Scholar
• Pennell PB. Antiepileptic drug pharmacokinetics during pregnancy and lactation. Neurology61(6 Suppl. 2), S35–S42 (2003).
   PubMed Web of Science ®Google Scholar
• Tran TA, Leppik IE, Blesi K, Sathanandan ST, Remmel R. Lamotrigine clearance during pregnancy. Neurology59(2), 251–255 (2002).
   PubMed Web of Science ®Google Scholar
• Pennell PB, Newport DJ, Stowe ZN, Helmers SL, Montgomery JQ, Henry TR. The impact of pregnancy and childbirth on the metabolism of lamotrigine. Neurology62(2), 292–295 (2004).
   PubMed Web of Science ®Google Scholar
• Binnie CD, Debets RM, Engelsman M et al. Double-blind crossover trial of lamotrigine (Lamictal) as add-on therapy in intractable epilepsy. Epilepsy Res.4(3), 222–229 (1989).
   PubMed Web of Science ®Google Scholar
• Boas J, Dam M, Friis ML, Kristensen O, Pedersen B, Gallagher J. Controlled trial of lamotrigine (Lamictal) for treatment-resistant partial seizures. Acta Neurol. Scand.94(4), 247–252 (1996).
   PubMed Web of Science ®Google Scholar
• Jawad S, Richens A, Goodwin G, Yuen WC. Controlled trial of lamotrigine (Lamictal) for refractory partial seizures. Epilepsia30(3), 356–363 (1989).
   PubMed Web of Science ®Google Scholar
• Loiseau P, Yuen AW, Duche B, Menager T, Arne-Bes MC. A randomised double-blind placebo-controlled crossover add-on trial of lamotrigine in patients with treatment-resistant partial seizures. Epilepsy Res.7(2), 136–145 (1990).
   PubMed Web of Science ®Google Scholar
• Matsuo F, Bergen D, Faught E et al. Placebo-controlled study of the efficacy and safety of lamotrigine in patients with partial seizures. U.S. Lamotrigine Protocol 0.5 Clinical Trial Group. Neurology43(11), 2284–2291 (1993).
   PubMed Web of Science ®Google Scholar
• Messenheimer J, Ramsay RE, Willmore LJ et al. Lamotrigine therapy for partial seizures: a multicenter, placebo-controlled, double-blind, cross-over trial. Epilepsia35(1), 113–121 (1994).
   PubMed Web of Science ®Google Scholar
• Sander JW, Patsalos PN, Oxley JR, Hamilton MJ, Yuen WC. A randomised double-blind placebo-controlled add-on trial of lamotrigine in patients with severe epilepsy. Epilepsy Res.6(3), 221–226 (1990).
   PubMed Web of Science ®Google Scholar
• Schapel GJ, Beran RG, Vajda FJ et al. Double-blind, placebo controlled, crossover study of lamotrigine in treatment resistant partial seizures. J. Neurol. Neurosurg. Psychiatry56(5), 448–453 (1993).
   PubMed Web of Science ®Google Scholar
• Smith D, Baker G, Davies G, Dewey M, Chadwick DW. Outcomes of add-on treatment with lamotrigine in partial epilepsy. Epilepsia34(2), 312–322 (1993).
   PubMed Web of Science ®Google Scholar
• Brodie MJ, Richens A, Yuen AW. Double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. UK Lamotrigine/Carbamazepine Monotherapy Trial Group. Lancet345(8948), 476–479 (1995).
   PubMed Web of Science ®Google Scholar
• Brodie MJ, Overstall PW, Giorgi L. Multicentre, double-blind, randomised comparison between lamotrigine and carbamazepine in elderly patients with newly diagnosed epilepsy. The UK Lamotrigine Elderly Study Group. Epilepsy Res.37(1), 81–87 (1999).
   PubMed Web of Science ®Google Scholar
• Steiner TJ, Dellaportas CI, Findley LJ et al. Lamotrigine monotherapy in newly diagnosed untreated epilepsy: a double-blind comparison with phenytoin. Epilepsia40(5), 601–607 (1999).
   PubMed Web of Science ®Google Scholar
• Brodie MJ, Chadwick DW, Anhut H et al. Gabapentin versus lamotrigine monotherapy: a double-blind comparison in newly diagnosed epilepsy. Epilepsia43(9), 993–1000 (2002).
   PubMed Web of Science ®Google Scholar
• Rowan AJ, Ramsay RE, Collins JF et al. New onset geriatric epilepsy: a randomized study of gabapentin, lamotrigine, and carbamazepine. Neurology64(11), 1868–1873 (2005).
   PubMed Web of Science ®Google Scholar
• Faught E, Matsuo FU, Schachter S, Messenheimer J, Womble GP. Long-term tolerability of lamotrigine: data from a 6-year continuation study. Epilepsy Behav.5(1), 31–36 (2004).
   PubMed Web of Science ®Google Scholar
• Duchowny M, Pellock JM, Graf WD et al. A placebo-controlled trial of lamotrigine add-on therapy for partial seizures in children. Lamictal Pediatric Partial Seizure Study Group. Neurology53(8), 1724–1731 (1999).
   PubMed Web of Science ®Google Scholar
• Besag FM, Wallace SJ, Dulac O, Alving J, Spencer SC, Hosking G. Lamotrigine for the treatment of epilepsy in childhood. J. Pediatr.127(6), 991–997 (1995).
   PubMed Web of Science ®Google Scholar
• Parmeggiani L, Belmonte A, Ferrari AR, Perucca E, Guerrini R. Add-on lamotrigine treatment in children and young adults with severe partial epilepsy: an open, prospective, long-term study. J. Child Neurol.15(10), 671–674 (2000).
   PubMed Web of Science ®Google Scholar
• Sharpe C, Buchanan N. Juvenile myoclonic epilepsy: diagnosis, management and outcome. Med. J. Aust.162(3), 133–134 (1995).
   PubMedGoogle Scholar
• Biton V, Sackellares JC, Vuong A, Hammer AE, Barrett PS, Messenheimer JA. Double-blind, placebo-controlled study of lamotrigine in primary generalized tonic-clonic seizures. Neurology65(11), 1737–1743 (2005).
   PubMed Web of Science ®Google Scholar
• Prasad A, Kuzniecky RI, Knowlton RC et al. Evolving antiepileptic drug treatment in juvenile myoclonic epilepsy. Arch. Neurol.60(8), 1100–1105 (2003).
   PubMedGoogle Scholar
• Morris GL, Hammer AE, Kustra RP, Messenheimer JA. Lamotrigine for patients with juvenile myoclonic epilepsy following prior treatment with valproate: results of an open-label study. Epilepsy Behav.5(4), 509–512 (2004).
   PubMedGoogle Scholar
• Guerrini R, Dravet C, Genton P, Belmonte A, Kaminska A, Dulac O. Lamotrigine and seizure aggravation in severe myoclonic epilepsy. Epilepsia39(5), 508–512 (1998).
   PubMed Web of Science ®Google Scholar
• Crespel A, Genton P, Berramdane M et al. Lamotrigine associated with exacerbation or de novo myoclonus in idiopathic generalized epilepsies. Neurology65(5), 762–764 (2005).
   PubMed Web of Science ®Google Scholar
• Motte J, Trevathan E, Arvidsson JF, Barrera MN, Mullens EL, Manasco P. Lamotrigine for generalized seizures associated with the Lennox–Gastaut syndrome. Lamictal Lennox–Gastaut Study Group. N. Engl. J. Med.337(25), 1807–1812 (1997).
   PubMed Web of Science ®Google Scholar
• Donaldson JA, Glauser TA, Olberding LS. Lamotrigine adjunctive therapy in childhood epileptic encephalopathy (the Lennox–Gastaut syndrome). Epilepsia38(1), 68–73 (1997).
   PubMed Web of Science ®Google Scholar
• Veggiotti P, Cieuta C, Rex E, Dulac O. Lamotrigine in infantile spasms. Lancet344(8933), 1375–1376 (1994).
   PubMed Web of Science ®Google Scholar
• Cianchetti C, Pruna D, Coppola G, Pascotto A. Low-dose lamotrigine in West syndrome. Epilepsy Res.51(1–2), 199–200 (2002).
   PubMed Web of Science ®Google Scholar
• Uldall P, Hansen FJ, Tonnby B. Lamotrigine in Rett syndrome. Neuropediatrics24(6), 339–340 (1993).
   PubMedGoogle Scholar
• Calabrese JR, Bowden CL, Sachs G et al. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder. J. Clin. Psychiatry64(9), 1013–1024 (2003).
   PubMed Web of Science ®Google Scholar
• Goodwin GM, Bowden CL, Calabrese JR et al. A pooled analysis of 2 placebo-controlled 18-month trials of lamotrigine and lithium maintenance in bipolar I disorder. J. Clin. Psychiatry65(3), 432–441 (2004).
   PubMed Web of Science ®Google Scholar
• Fatemi SH, Rapport DJ, Calabrese JR, Thuras P. Lamotrigine in rapid-cycling bipolar disorder. J. Clin. Psychiatry58(12), 522–527 (1997).
   PubMed Web of Science ®Google Scholar
• Calabrese JR, Suppes T, Bowden CL et al. A double-blind, placebo-controlled, prophylaxis study of lamotrigine in rapid-cycling bipolar disorder. Lamictal 614 Study Group. J. Clin. Psychiatry61(11), 841–850 (2000).
   PubMed Web of Science ®Google Scholar
• Simpson DM, Olney R, McArthur JC, Khan A, Godbold J, Ebel-Frommer K. A placebo-controlled trial of lamotrigine for painful HIV-associated neuropathy. Neurology54(11), 2115–2119 (2000).
   PubMed Web of Science ®Google Scholar
• Pappagallo M. Newer antiepileptic drugs: possible uses in the treatment of neuropathic pain and migraine. Clin. Ther.25(10), 2506–2538 (2003).
   PubMed Web of Science ®Google Scholar
• Simpson DM, McArthur JC, Olney R et al. Lamotrigine for HIV-associated painful sensory neuropathies: a placebo-controlled trial. Neurology60(9), 1508–1514 (2003).
   PubMed Web of Science ®Google Scholar
• Eisenberg E, Lurie Y, Braker C, Daoud D, Ishay A. Lamotrigine reduces painful diabetic neuropathy: a randomized, controlled study. Neurology57(3), 505–509 (2001).
   PubMed Web of Science ®Google Scholar
• Vestergaard K, Andersen G, Gottrup H, Kristensen BT, Jensen TS. Lamotrigine for central poststroke pain: a randomized controlled trial. Neurology56(2), 184–190 (2001).
   PubMed Web of Science ®Google Scholar
• Lampl C, Katsarava Z, Diener HC, Limmroth V. Lamotrigine reduces migraine aura and migraine attacks in patients with migraine with aura. J. Neurol. Neurosurg. Psychiatry76(12), 1730–1732 (2005).
   PubMed Web of Science ®Google Scholar
• Pascual J, Caminero AB, Mateos V et al. Preventing disturbing migraine aura with lamotrigine: an open study. Headache44(10), 1024–1028 (2004).
   PubMed Web of Science ®Google Scholar
• Leone M, Rigamonti A, Usai S, Damico D, Grazzi L, Bussone G. Two new short-lasting, unilateral with conjunctival injection and tearing (SUNCT) cases responsive to lamotrigine. Cephalalgia20(9), 845–847 (2000).
   PubMed Web of Science ®Google Scholar
• Messenheimer J, Mullens EL, Giorgi L, Young F. Safety review of adult clinical trial experience with lamotrigine. Drug Saf.18(4), 281–296 (1998).
   PubMed Web of Science ®Google Scholar
• Tidwell A, Swims M. Review of the newer antiepileptic drugs. Am. J. Manag. Care9(3), 253–276; quiz 277–259 (2003).
   PubMedGoogle Scholar
• Buzan RD, Dubovsky SL. Recurrence of lamotrigine-associated rash with rechallenge. J. Clin. Psychiatry59(2), 87 (1998).
   PubMedGoogle Scholar
• Tavernor SJ, Wong IC, Newton R, Brown SW. Rechallenge with lamotrigine after initial rash. Seizure4(1), 67–71 (1995).
   PubMedGoogle Scholar
• Hirsch LJ, Weintraub DB, Buchsbaum R et al. Predictors of lamotrigine-associated rash. Epilepsia47(2), 318–322 (2006).
   PubMed Web of Science ®Google Scholar
• Mockenhaupt M, Messenheimer J, Tennis P, Schlingmann J. Risk of Stevens–Johnson syndrome and toxic epidermal necrolysis in new users of antiepileptics. Neurology64(7), 1134–1138 (2005).
   PubMed Web of Science ®Google Scholar
• Biton V, Mirza W, Montouris G, Vuong A, Hammer AE, Barrett PS. Weight change associated with valproate and lamotrigine monotherapy in patients with epilepsy. Neurology56(2), 172–177 (2001).
   PubMed Web of Science ®Google Scholar
• Fayad M, Choueiri R, Mikati M. Potential hepatotoxicity of lamotrigine. Pediatr. Neurol.22(1), 49–52 (2000).
   PubMed Web of Science ®Google Scholar
• Makin AJ, Fitt S, Williams R, Duncan JS. Fulminant hepatic failure induced by lamotrigine. Br. Med. J.311(7000), 292 (1995).
   PubMedGoogle Scholar
• Overstreet K, Costanza C, Behling C, Hassanin T, Masliah E. Fatal progressive hepatic necrosis associated with lamotrigine treatment: a case report and literature review. Dig. Dis. Sci.47(9), 1921–1925 (2002).
   PubMed Web of Science ®Google Scholar
• Sauve G, Bresson-Hadni S, Prost P et al. Acute hepatitis after lamotrigine administration. Dig. Dis. Sci.45(9), 1874–1877 (2000).
   PubMed Web of Science ®Google Scholar
• Mecarelli O, Pulitano P, Mingoia M et al. Acute hepatitis associated with lamotrigine and managed with the molecular adsorbents recirculating system (Mars). Epilepsia46(10), 1687–1689 (2005).
   PubMed Web of Science ®Google Scholar
• Sotero de Menezes MA, Rho JM, Murphy P, Cheyette S. Lamotrigine-induced tic disorder: report of five pediatric cases. Epilepsia41(7), 862–867 (2000).
   PubMedGoogle Scholar
• Ketter TA, Post RM, Theodore WH. Positive and negative psychiatric effects of antiepileptic drugs in patients with seizure disorders. Neurology53(5 Suppl. 2), S53–S67 (1999).
   PubMed Web of Science ®Google Scholar
• Sadler M. Lamotrigine associated with insomnia. Epilepsia40(3), 322–325 (1999).
   PubMedGoogle Scholar
• Meador KJ, Loring DW, Vahle VJ et al. Cognitive and behavioral effects of lamotrigine and topiramate in healthy volunteers. Neurology64(12), 2108–2114 (2005).
   PubMed Web of Science ®Google Scholar
• Weintraub D, Buchsbaum R, Spencer HT et al. Cognitive side effects of the newer antiepileptic drugs: results from the Columbia antiepileptic drug database. Neurology62(Suppl. 5), A311 (2004).
   Google Scholar
• Pressler RM, Binnie CD, Coleshill SG, Chorley GA, Robinson RO. Effect of lamotrigine on cognition in children with epilepsy. Neurology66(10), 1495–1499 (2006).
   PubMedGoogle Scholar
• Hirsch LJ, Weintraub D, Buchsbaum R et al. Psychiatric side effects of the newer antiepileptic drugs: results from the Columbia antiepileptic drug database. Neurology62(Suppl. 5), A309 (2004).
   Google Scholar
• Cantero J, Weintraub D, Buchsbaum R, Hirsch LJ. Cosmetic side effects of the antiepileptic drugs. Epilepsia45(Suppl. 7), 306–307 (2004).
   Google Scholar
• Pellock JM. Overview of lamotrigine and the new antiepileptic drugs: the challenge. J. Child Neurol.12(Suppl. 1), S48–S52 (1997).
   Google Scholar
• Dooley J, Camfield P, Gordon K, Camfield C, Wirrell Z, Smith E. Lamotrigine-induced rash in children. Neurology46(1), 240–242 (1996).
   PubMedGoogle Scholar
• Pellock JM, Watemberg N. New antiepileptic drugs in children: present and future. Semin. Pediatr. Neurol.4(1), 9–18 (1997).
   PubMedGoogle Scholar
• Duchowny M, Gilman J, Messenheimer J, Womble G, Risner M. Long-term tolerability and efficacy of lamotrigine in pediatric patients with epilepsy. J. Child Neurol.17(4), 278–285 (2002).
   PubMedGoogle Scholar
• Besag FM, Dulac O, Alving J, Mullens EL. Long-term safety and efficacy of lamotrigine (Lamictal) in paediatric patients with epilepsy. Seizure6(1), 51–56 (1997).
   PubMedGoogle Scholar
• Weintraub D, Resor SR Jr, Bazil CW, Hirsch LJ. Head-to-head comparison of antiepileptic drug effectiveness in adults with epilepsy. Neurology64(Suppl. 1), A188 (2005).
   PubMedGoogle Scholar
• Nieto-Barrera M, Brozmanova G, Capovilla W et al. A comparison of monotherapy with lamotrigine or carbamazepine in patients with newly diagnosed partial epilepsy. Epilepsy Res.46(2), 145–155 (2001).
   Google Scholar
• Reunanen M, Dam M, Yuen, AWC. A randomised open multicentre comparitive trial of lamotrigine and carbamazepine monotherapy in patients with newly diagnosed or recurrent epilepsy. Epilepsy Res.23, 149–155 (1996).
   Google Scholar